Passage Bio Inc (NAS:PASG)
$ 0.7925 -0.0075 (-0.94%) Market Cap: 49.41 Mil Enterprise Value: -11.14 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Passage Bio Inc Company Update Call Transcript

Dec 17, 2021 / 01:00PM GMT
Release Date Price: $6.64 (+3.59%)
Operator

Thank you for holding. Good morning, and welcome to the Passage Bio conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn it over to Stuart Henderson, Vice President of Investor Relations and Strategic Finance. Stuart, please proceed.

Stuart M. Henderson
Passage Bio, Inc. - VP IR & Strategic Finance

Thank you, operator, and good morning, everyone. Today, we will review interim results from the Global Imagine-1 Phase II -- Phase I/II clinical trial of PBGM01 in infantile GM1 gangliosidosis. Please refer to the press release issued earlier and the slides that we will be using on today's call on the Investors and News section of the Passage Bio website.

On today's call, Bruce Goldsmith, President and Chief Executive Officer; and Dr. Eliseo Salinas, Chief R&D Officer, will review the interim results. Following the presentation, Dr. James Wilson, Director of the University of Pennsylvania's gene therapy program will join Bruce and Eliseo for Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot